The International Working Group on the Diabetic Foot (IWGDF) now recommends the use of Reapplix’s technology, the 3C Patch®, an autologous combined leucocyte, platelet and fibrin, as an adjunctive treatment.
The recommendation is published in new guidelines on the Prevention and Management of Diabetic Foot Disease and is based on Reapplix’s substantial body of evidence supporting the use of 3C Patch®, including a Randomised Controlled Trial recently published in The Lancet journal.
Co-founder and Chief Scientific Officer, Rasmus Lundquist commented “We are very excited to be included in this well-respected, independent international guideline. Wound care nurses refer to the guidelines when seeking solutions to difficult to heal wounds and in that respect, I am convinced that the publication will support our commercialization efforts and dialogue with health authorities. This is a major acknowledgement of our continued efforts to provide an effective and proven technology for the treatment of diabetic foot ulcers to patients and healthcare professionals.”
Read the full guideline here https://iwgdfguidelines.org/wp-content/uploads/2019/05/06-IWGDF-recommendations-wound-healing-2019.pdf
Graeme Brookes, CEO
+45 53 77 74 47
In 1996 the International Working Group on the Diabetic Foot (IWGDF) was created to develop Guidelines on the prevention and management of diabetic foot complications. These are the only international and multidisciplinary Guidelines that are produced through a rigorous, scientific process undertaken by health professionals and researchers from all over the world. In addition, the IWGDF produces systematic reviews and a summary for daily practice, which are all published in an international scientific journal and on the working group’s website https://iwgdfguidelines.org
Founded in 2008, Reapplix is a privately held wound care company backed by leading Danish institutional investors that has developed a novel platform technology for Regenerative Medicine. Its innovative, patented 3C Patch® System draws on the individual patient’s capacity to heal and is clinically proven to accelerate the healing of diabetic foot ulcers. Reapplix won the Danish 2018 EY Entrepreneur of the Year Award in the life science category.